Theravectys SA – Product Pipeline Review

Global Markets Direct’s, ‘Theravectys SA – Product Pipeline Review – 2016’, provides an overview of the Theravectys SA’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Theravectys SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Theravectys SA

The report provides overview of Theravectys SA including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Theravectys SA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Theravectys SA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Theravectys SA’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Theravectys SA

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Theravectys SA’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Theravectys SA Snapshot 6

Theravectys SA Overview 6

Key Facts 6

Theravectys SA - Research and Development Overview 7

Key Therapeutic Areas 7

Theravectys SA - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Theravectys SA - Pipeline Products Glance 12

Theravectys SA - Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Theravectys SA - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Theravectys SA - Drug Profiles 14

Cellular Immunotherapy to Inhibit PD1 for Oncology - Drug Profile 14

Product Description 14

Mechanism Of Action 14

R&D Progress 14

Cellular Immunotherapy to Target CD33 and CD123 for AML - Drug Profile 15

Product Description 15

Mechanism Of Action 15

R&D Progress 15

Cellular Immunotherapy to Target CTLA4 for Oncology - Drug Profile 16

Product Description 16

Mechanism Of Action 16

R&D Progress 16

Cellular Immunotherapy to Target PDL1 for Oncology - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

Epstein-Barr virus vaccine - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

hepatitis B vaccine - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

THV-01 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

THV-02 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

THV-03 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

THV-04 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Vaccine for Breast Cancer - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Vaccine for Glioblastoma Multiforme - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Vaccine for Hepatocellular Carcinoma - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Vaccine for HPV Associated Cancers - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Vaccine for Melanoma - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Vaccine for Multiple Myeloma - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Vaccine for Ovarian Cancer - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Vaccine for Prostate Cancer - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Theravectys SA - Pipeline Analysis 36

Theravectys SA - Pipeline Products by Target 36

Theravectys SA - Pipeline Products by Route of Administration 38

Theravectys SA - Pipeline Products by Molecule Type 39

Theravectys SA - Pipeline Products by Mechanism of Action 40

Theravectys SA - Dormant Projects 41

Theravectys SA - Locations And Subsidiaries 42

Head Office 42

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44

List of Tables

List of Tables

Theravectys SA, Key Facts 6

Theravectys SA – Pipeline by Indication, 2016 9

Theravectys SA – Pipeline by Stage of Development, 2016 10

Theravectys SA – Monotherapy Products in Pipeline, 2016 11

Theravectys SA – Phase II, 2016 12

Theravectys SA – Preclinical, 2016 13

Theravectys SA – Pipeline by Target, 2016 37

Theravectys SA – Pipeline by Route of Administration, 2016 38

Theravectys SA – Pipeline by Molecule Type, 2016 39

Theravectys SA – Pipeline Products by Mechanism of Action, 2016 40

Theravectys SA – Dormant Developmental Projects,2016 41

List of Figures

List of Figures

Theravectys SA – Pipeline by Top 10 Indication, 2016 8

Theravectys SA – Pipeline by Stage of Development, 2016 10

Theravectys SA – Monotherapy Products in Pipeline, 2016 11

Theravectys SA – Pipeline by Target, 2016 36

Theravectys SA – Pipeline by Molecule Type, 2016 39

Theravectys SA – Pipeline Products by Mechanism of Action, 2016 40

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports